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Abstract 
Recent research has demonstrated that a population of stem cells can be isolated from amniotic 
fluid removed by amniocentesis that are broadly multipotent and non-tumorogenic. These 
amniotic fluid-derived stem cells (AFSC) could potentially provide an autologous cell source for 
treatment of congenital defects identified during gestation, particularly cardiovascular defects. In 
this review, the various methods of isolating, sorting and culturing AFSC are compared, along 
with techniques for inducing differentiation into cardiac myocytes and endothelial cells. Though 
research has not demonstrated complete and high yield cardiac differentiation, AFSC have been 
shown to effectively differentiate into endothelial cells and can effectively support cardiac tissue. 
Additionally, several tissue engineering and regenerative therapeutic approaches for the use of 
these cells in heart patches, injection after myocardial infarction, heart valves, vascularized 
scaffolds and blood vessels are summarized. These applications show great promise in the 
treatment of congenital cardiovascular defects, and further studies of isolation, culture, and 
differentiation of AFSC will help to develop their use for tissue engineering, regenerative 
medicine, and cardiovascular therapies.  
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Introduction 
Birth defects are the number one cause of death in infants in the United States (1). 
Approximately 9200 invasive procedures were performed in infants with congenital heart disease 
in the US in 2010 (2). Many of these repairs require synthetic or acellular materials. Current 
myocardial patched repair, common for repair of septal defects and outflow tract obstructions, 
and conduit repair, or construction of a new conduit as in a Blalock-Taussig Shunt, generally 
uses Dacron, Teflon or fixed, acellular pericardium (3). However, these patches have been 
shown to increase the risk of sudden cardiac death by 25 to 100 times compared to a healthy 
population (4). Additionally, valve repair in infants can often make use of autologous valves (as 
in a Ross procedure, which uses the patient’s pulmonary valve to replace a damaged aortic 
valve), but many times a mechanical valve is required as xenotropic (animal) valves are seldom 
used in children due to concerns of long-term durability (5). These mechanical valves do not 
grow with the patient and require a lifetime of anticoagulation therapy with many side effects 
(6). Tissue engineered, or regenerative therapies to treat these pathologies, which result in living 
tissue that grows with the child, could greatly benefit this population. 
 Many advances in biomaterials and decellularized tissues in the last decade have aimed to 
generate scaffolds for tissue engineering repair of congenital heart defects (see review in (7)). 
However, very few of these have used living cells. The use of live and functioning cardiac cells 
in tissue-engineered cardiac scaffolds could allow for correction of large, full-thickness defects, 
maintenance of the normal conduction pathways in the heart, the creation of highly patent valves 
that grow with pediatric patients, and many other transformative technologies that have been 
thoroughly reviewed elsewhere (7-9) Though some therapies have seeded constructs with bone 
marrow mesenchymal stem cells (MSC) (10), these can be very difficult and risky to obtain 
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 5 
autologously in neonates. Additionally, concern about tumorogenesis has limited use of human 
embryonic and induced pluripotent stem cells. Because of the risks of immunorejection and the 
high risks of immunosuppressive drugs in infants, non-autologous transplanted cells are not a 
desirable option (11). In this article, we will discuss the characterization and use of stem cells 
isolated from amniotic fluid, which can be obtained with relatively low risk when birth defects 
are diagnosed in utero and used to construct tissue engineered and regenerative therapeutic 
tissues, using the fetus’ own cells, for the correction of these defects in the newborn. 
 
Amniotic fluid  
Amniotic fluid (AF) fills the amniotic cavity and acts to prevent adherence of the embryo 
to the amnion, absorb jolts to protect the embryo or fetus, and allow for fetal movement (12). 
Amniotic membrane cells produce some of the fluid, but the bulk of the liquid component comes 
from the maternal blood. Approximately one liter of AF surrounds the fetus by birth. Beginning 
in the fifth month the fetus will consume an estimated 400 ml of AF a day, and fetal urine is then 
added back to the fluid. The fetal urine is mostly water, as metabolic waste is exchanged through 
the placenta (12).  
For research applications the most common method to obtain amniotic fluid is through 
amniocentesis (13-17). Alternatively, fluid can be obtained from therapeutic amnioreductions in 
which large quantities of amniotic fluid are removed for treatment of conditions such as twin-
twin transfusion syndrome (18) or amniotic fluid may be collected during elective caesarean 
sections (19). 
 
Identification, isolation, and culture of undifferentiated stem cells in AF 
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The cells contained in AF are a heterogeneous mixture of many cell types derived from 
and genetically matched to the fetus (15, 20). The predominant phenotype observed is epithelial 
cells, but cells expressing mesenchymal, osteocyte, adipocyte, and neuronal markers are also 
present (20). 
AF was first found to contain Oct-4 positive cells in 2003 (16). Oct-4 is a transcription 
factor necessary for embryonic stem cell pluripotency (21). In 2007, AF was determined to 
contain a population of broadly multipotent stem cells (15). Adherent cells from amniocentesis 
were immunoselected for c-kit expression using magnetic microsphere assisted cell sorting. C-
kit, or CD117, is a tyrosine-kinase transmembrane receptor for stem cell factor, also known as 
mast cell growth factor, which is a pleiotropic factor involved in development and known to be 
required in hematopoiesis in adults (22). Clonal colonies were generated from adherent, c-kit-
sorted cells and tracked by retroviral marking. It was found that some clonal colonies were able 
to differentiate towards adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic 
lineages, representing cell types of all three germ layers (15). Even though amniotic fluid-
derived stem cells (AFSC) are broadly multipotent, they did not form teratomas when implanted 
in severe combined immunodeficiency (SCID) mice (15). This non-tumor forming property, 
which is a similarity AFSC share with adult stem cells, could be an advantage over human 
embryonic stem cells when medical applications are considered.   
Despite this early promise with stem cells from AF, much work remains before their 
potential can be realized. Many differences still exist in the methods research labs use for 
culturing and isolating AFSC. While many researchers appear to use the same method as the 
Atala lab described above, variation does exist. A summary of isolation and culture conditions 
for maintaining undifferentiated AFSC currently published can be found in Table 1 (culture 
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 7 
conditions used for AFSC tested for cardiovascular tissue engineering marked with *). In 
addition to the culture methods for maintaining undifferentiated stem cells, researchers are 
examining culture conditions to promote particular cell types, such as advanced Dulbecco’s 
minimal essential medium with 5% fetal bovine serum results in the enrichment of epithelial cell 
population (14). 
AFSC are the subject of ongoing interest and research. Isolation, culture, and 
cryopreservation of AFSC are ongoing areas of investigation in the field (19, 23-28). 
Additionally, some researchers are comparing AFSC to other fetal-derived tissues such as 
umbilical cord blood and amniotic membrane (27, 29, 30). AFSC are being explored for use in 
tissue engineering applications for a variety of tissue types. This review focuses on 
cardiovascular cell types and tissue engineering, which are addressed further below, but AFSC 
are also being investigated for osteogenic (13, 31, 32), renal (33, 34), myogenic (35), epithelial 
(36, 37), and neuronal (14, 38-45) differentiation and tissue engineering.  
An area of contention that remains with AFSC is whether sorting for c-kit expression is 
necessary or appropriate. Approximately 1% of total amniotic fluid cells are positive for c-kit 
(15, 34). One research group studying neuronal differentiation investigated the ability of c-kit 
sorted cells compared to unsorted cells to differentiate towards a neuronal lineage (14).  It was 
found that the unsorted population was better able to differentiate towards a neuronal lineage 
than the sorted population. However, the c-kit sorted population was better able to differentiate 
towards adipogenic, osteogenic, and chondrogenic lineages (14). These findings, in combination 
with the lack of agreement in the field on isolation and culture procedures, indicate further 
research is needed to determine and validate the appropriate isolation procedures for cells from 
AF capable of differentiation into cardiovascular cell types. Furthermore, it may be necessary to 
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 8 
distinguish distinct populations of AF cells that may be better suited for various therapeutic end 
points. 
Analysis of the undifferentiated AFSC populations is necessary to understand the starting 
populations of cells in differentiation experiments. Furthermore, the different culture conditions 
used for the undifferentiated stem cells necessitates analysis of the undifferentiated stem cells to 
determine if the starting populations across experiments are similar and comparable. A summary 
of markers analyzed on undifferentiated AFSC can be found in Table 2. AFSC were found to be 
positive for markers common of mesenchymal stem cells: CD29 or integrin beta-1 (17-19, 24, 
25, 30, 40, 41, 46-51), CD44 or hyaluronate receptor (17, 18, 20, 23, 25, 28-30, 40, 41, 47-52), 
CD73 or ecto-5’-nucleotidase (17-20, 23-25, 28, 40, 46-50), CD90 or Thy-1 (17-19, 23, 24, 28, 
40, 46-52), CD105 or endoglin (17-19, 23-25, 28, 30, 40, 46-52), and CD146 or melanoma cell 
adhesion molecule (25, 47, 48). The stem cells were also found to be negative for endothelial 
markers CD31 (18, 19, 24-26, 47, 49, 50, 53), CD144 (25), and CD309 (25) and for 
hematopoietic markers CD11b (17), CD14 (17, 25, 40, 51), CD34 (17, 25, 28, 30, 41, 46-51), 
and CD45 (18, 19, 23-25, 28, 40, 41, 46-52). AFSC were positive for vimentin (23, 26, 35, 40, 
46, 47, 52-54), an intermediate filament commonly found in mesenchymal cells, and negative for 
desmin (26, 53), an intermediate filament found in the Z-line of sarcomeres in muscle cells. 
AFSC were positive for MHCI (17, 18, 23, 25, 28, 30, 41, 47, 50), also know as HLA-ABC, and 
negative for MHCII (17, 18, 23, 30, 41, 47, 50, 52), also known as HLA-DR. SSEA-4, a surface 
antigen commonly found on embryonic stem cells, was positive on AFSC by flow cytometry and 
immunostaining (18, 23, 30, 35, 46, 49-52, 54). Results for expression of c-kit or CD117 in 
AFSC were mixed: some research demonstrated positive gene expression by PCR (37), but flow 
cytometry results were negative (17, 49, 50) or slightly (~25%) positive (18). Oct4, Sox2, and 
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Nanog, transcription factors necessary for maintaining pluirpotency in embryonic stem cells, also 
displayed mixed results across different studies of AFSC (16, 17, 20, 23, 24, 29-31, 35, 37, 39-
41, 46, 48-52, 54).  
 
In vitro cardiac myocyte differentiation of AFSC 
AFSC have been investigated for cardiac tissue engineering (55). AFSC applications to in 
vitro cardiac tissue engineering are summarized in this section and Table 3. The most common 
method tested for differentiation of AFSC towards a cardiac lineage is direct co-cultures of 
AFSC and neonatal rat ventricular myocytes (NRVM), in which the two cell types are mixed and 
plated together (46-48, 50, 52). Additionally, some scientific groups have used AFSC for cell 
seeding of heart valves, such as seeding a fibrin gel as a cell carrier for AFSC for heart valve 
engineering (56).  
Undifferentiated c-kit sorted AFSC have been shown to express some genes common in 
cardiac cells, including sarcomeric proteins myosin light chain 2v (MLC2v) and β-myosin heavy 
chain (MHC); transcription factors Nkx2.5, Gata4, Mef 2C, and Mef 2D; gap junction protein 
connexin 43; and adhesion proteins N- and H-cadherin (47, 48). However, no protein expression 
was observed of MLC2v, β-MHC, Nkx2.5, or Gata4 (47). While connexin 43 and cadherins were 
observed at the protein level, they did not localize to the membrane in undifferentiated AFSC 
(47). It is important for researchers to understand the common gene expression between AFSC 
and cardiomyocytes because during differentiation gene expression is commonly examined to 
evaluate the extent of differentiation. Therefore it is necessary to correctly understand the 
starting state of the AFSC in order to evaluate the effectiveness of tested differentiation methods. 
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Additionally, expression of cardiac specific genes, even in the absence of protein expression, 
may support the hypothesis that AFSC are capable of cardiomyocyte differentiation (48).  
In 2007, Chiavegato et al. studied cardiac differentiation of c-kit sorted human AFSC 
(47). The AFSC were labeled with a fluorescent dye and mixed with NRVM at a ratio of 1:4, 
respectively. These cells were plated on gelatin-coated surfaces and cultured for 10 days, at 
which time immunofluorescence was performed. Approximately 5% of labeled AFSC displayed 
cardiac troponin I (cTnI) expression and showed A and I bands of sarcomeres at high 
magnification. However, at least some of these cells also appeared to have double nuclei, which 
the authors suggest supports a cell fusion explanation, rather than differentiation of the stem cells 
(47). Similarly, Iop et al. observed that in co-cultures of rat AFSC with NRVM, approximately 
3.5% of rat AFSC expressed sarcomeric myosin or cardiac troponin T (cTnT). Again, many cells 
had more than one nuclei and the authors remained unsure if this occurrence of double nuclei is 
due to cell fusion or dividing cells (52). 
Further co-culture studies of rat AFSC demonstrated additional promise of the use of 
AFSC in cardiac tissue engineering. In one example, rat AFSC were isolated by c-kit sorting 
from animals expressing green fluorescent protein (GFP), which facilitated separation of NRVM 
from GFP negative rats.  It was found that these undifferentiated rat AFSC had low levels of 
protein expression of both MHC I and MHC II (46). After 4 days of co-culture with NRVM, 
some AFSC in cell clusters rich in NRVM expressed cTnI and MHC proteins, but only a 
minority of these clusters containing AFSC were beating. After 9 days, cardiac sarcomeric α-
actinin was also detected in some AFSC. As in previously described co-culture experiments, 
some bi-nucleated cells were detectable, suggesting that at least some of these events may be due 
to cell fusion. Furthermore, myocardial differentiation of the AFSC was found to be 
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approximately 16% of AFSC after 9 days of co-culture. Electrical stimulation studies were also 
conducted to promote differentiation towards a cardiac lineage (46). Undifferentiated AFSC 
could not be excited through electrical stimulation, but after co-culture they developed electrical 
excitability. Interestingly, only those AFSC that were in close contact with NRVM in the co-
cultures developed this excitability, suggesting that either cell fusion or short range signals may 
be mediating this transformation.  
A later study by Guan et al. supported that co-cultures with NRVM could induce human 
AFSC to differentiate towards a cardiogenic lineage by observing observations that AFSC in co-
culture with NRVM could form functional gap junctions between the two cell types (48). 
Additionally, connexin 43 and N-cadherin were seen to localize to the membrane in AFSC in co-
culture with NRVM. Functional gap junctions and connexin 43 or N-cadherin localization to the 
membrane were not observed in cultures of AFSC alone or AFSC-fibroblast co-cultures (48).  
AF cells cultured without a c-kit sorting step in a growth media of αMEM, 20% FBS, and 
4ng/ml basic fibroblast growth factor (bFGF) have also been tested for ability to differentiate 
down a cardiac lineage (50). Again the AF cells were directly mixed and plated with NRVM, 
then cultured for 10 days. Cells were stained with antibodies specific for human mitochondria, as 
well as antibodies to α-actinin and cTnT. Some cells stained positive for both human 
mitochondria, α-actinin and cTnT. Connexin 43 was observed at the junctions between AFSC 
and NRVM (50). 
NRVM-conditioned media and a cardiomyogenic differentiation medium (60% DMEM, 
28% MCDB-201, 10
-4
M ascorbate phosphate, 10
-9
M dexamethasone, 10% fetal bovine serum, 
1% antibiotics, and 1% ITS+ medium supplement) previously used on MSC (57) have also been 
tested on both human and rat AFSC (46, 47, 52). No changes were observed in the protein 
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expression of these two conditions, compared to undifferentiated AFSC after a 10-day culture 
period (46, 47, 52). These results suggest that either fusion or specific features of NRVM, such 
as cell-cell contact or short range soluble signals may be the cause of observed differentiation 
behavior in co-cultures. 
Cardiac differentiation of AFSC using treatment with 10 μM 5-aza-2’deoxycytidine for 
24 hours has also been tested. After the 24-hour treatment, cell culture continued in DMEM with 
10% horse serum, 10% fetal bovine serum, and antibiotics, AFSC became enlarged and 
developed organized stress fibers. At days 5 and 10 qRT-PCR showed progressive increases in 
cTnI and cTnT, as well as a reduction in Sox2, a transcription factor found in undifferentiated 
embryonic stem cells (48). Despite these results, no mature sarcomeres or spontaneous beating 
was observed, suggesting that additional cues may be necessary to obtain complete cardiac 
differentiation.  
While these techniques have potential, they are also deficient in ways that merit future 
consideration.  First, while there has been some success with c-kit sorted cells, c-kit expression is 
not maintained after subsequent passages (18, 47, 58). This would seem to suggest that c-kit 
itself may not be the most important factor in determining cardiac differentiation potential and 
that future exploration and characterization of AFSC is necessary.  Additionally, the 
differentiation of AFSC towards cardiomyogenic lineage versus cell fusion between AFSC and 
NRVM is an important issue that needs to be further addressed. This is particularly pertinent 
since, in other tissue systems, cell fusion has been shown to be the major reason for 
transdifferentiation of developmentally mature tissues from one tissue to another. The occurrence 
of cell fusion could limit the application of co-cultures for immunogenic reasons. 
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Implantation of AFSC after myocardial infarct 
In addition to the differentiation of AFSC towards a cardiac lineage, another area of 
interest has been the implantation of cells into cardiac tissue following myocardial infarction 
(MI). This work is motivated by similar studies performed using MSC, which have been shown 
to improve cardiac function when injected into the heart post-MI (59-62). A summary of AFSC 
implantation studies and results can be found in Table 4.  
 
Injection of dissociated AFSC 
Yeh et al. has previously demonstrated that injection of unsorted, undifferentiated human 
AFSC into rats at the border zone of infarct regions one week after MI caused by left coronary 
artery ligation led to superior cardiac function over saline injected controls (50). The AFSC 
treated group had significantly less myocardial fibrosis and enlargement of the left ventricle than 
the saline control group. Some cells double-stained positive for human nuclei and cardiac 
markers Nkx2.5, α-actinin, or cTnT. Again in this instance, the authors point out that it is 
unknown whether these double-positive cells resulted from differentiation of the AFSC or cell 
fusion of the AFSC with the rat cardiomyocytes (50).  Other researchers observed cells double 
positive for human-specific anti-platelet non-muscle myosin (hptMyosin) antibody and cTnT 
after injection of AFSC into rat hearts. However, the hptMyosin+ cells still had protein 
expression of SSEA4, so at best an incomplete transition to cardiomyocytes was achieved (47). 
Iop et al. have also compared rat bone marrow MSC (BM-MSC) to rat AFSC for cell 
therapy by injecting each into the periphery of cryoinjured areas on rat hearts (52). Fewer AFSC 
than BM-MSC were present in the injected area after 24 hours, but approximately equal numbers 
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were found after 30 days. Through analysis of mitotic marker phospho-Histone H3 and apoptotic 
markers, the researchers investigated this occurrence. The amount of apoptotic cells was 
consistent between the two cell types, but more mitotic cells, and therefore more proliferation, 
were observed in AFSC. This difference between the two cell types resulted from the superior 
proliferative capacity of AFSC. It was also found that 34.6% of BM-MSC and 49.6% of AFSC 
underwent differentiation in vivo to express either cTnT, von Willebrand factor or smooth 
muscle α-actin. BM-MSCs formed arterioles, but AFSC only formed capillaries as AFSC 
appeared to be unable to give rise to SM α-actin+ cells (52). However, another study found that 
rat AFSC were observed to express smooth muscle α-actin and be located in both arterioles and 
capillaries several weeks after injection into a ischemia/reperfusion injury in rats (46). The 
conflicting results of differentiation of rat AFSC following injected into injured myocardium 
indicates that more work remains to be done on the differentiation potential and the in vivo 
beneficial effects of AFSC. 
 
Injection of aggregated AFSC-ECM structures 
While dilation of the left ventricle is significantly reduced in rats injected with 
dissociated AFSC post-MI, an even greater effect has been found by injecting fragmented cell 
sheets or cell bodies of AFSC (49, 54). One week after acute MI, saline, dissociated AFSC, or 
aggregates of AFSC in the form of fragmented cell sheets or cell bodies were injected into the 
border of the infarct zone (49, 54). Both forms of AFSC aggregates were compared to saline and 
dissociated AFSC, but not to the other type of aggregate. 
To form injectable cell sheet fragments, human AFSC were plated on collagen I coated 
thermo-responsive methylcellulose hydrogels. Once a confluent cell layer was obtained, a sterile 
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mesh compressed the cell sheet to separate it into fragments. At room temperature the hydrogel 
system liquefied and the cell sheet fragments were collected (54). To form AFSC aggregates, the 
cells were plated into a 96-well plate coated with methylcellulose hydrogel. Cells do not attach to 
the surface of the methylcellulose hydrogel and instead aggregate to form spherical cell bodies 
(49).  
In both the case of cell sheets and cell bodies, the undifferentiated state of AFSC was 
maintained, as evidenced by expression of vimentin, a common marker of MSC, and SSEA-4, a 
marker of embryonic stem cells (ESC) (49, 54). Additionally these methods allowed for 
collection of cell sheets with the endogenous ECM maintained, which improved cell retention 
and survival following injection (49, 54).  
It was found that dissociated AFSC were quickly lost after injection. Lee et al. tracked 
injected cells using bioluminescene, and while AFSC remained for 4 weeks in rats injected with 
cell bodies, the signal was barely detectable after 7 days in rats injected with dissociated cells 
(49). This finding is corroborated by the cell sheet fragment study, which found few AFSC by 
histological analysis in the dissociated AFSC injected rats at the end of the 4 week experiment 
compared to the large numbers of AFSC found in rats injected with cell sheet fragments (54). In 
both cases, the authors hypothesized that the improved engraftment was due to the large size of 
the cell-ECM aggregates, thus allowing for entrapment in interstitial spaces (49, 54). 
Additionally, evidence of proliferation of AFSC was found in the cell sheet fragment group (54).  
While injection of dissociated AFSC demonstrated improved contractile function of the 
LV, injection of AFSC aggregates led to a significant function improvement over both saline and 
dissociated AFSC injections. Improvement was seen in the reduced size of the infarct area and 
improved left ventricular function in the aggregate treated groups compared to the dissociated 
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cell and saline treated groups (49, 54). Density of vasculature was also higher in cell sheet 
fragment group than saline and dissociated AFSC injected groups (54). 
 
AFSC are cardioprotective after MI 
AFSC have been demonstrated to be cardioprotective if injected immediately following 
acute myocardial infarction (MI) (63). In one experiment, immediately following MI caused by 
ligation of the left anterior descending coronary artery in adult rats, the hearts were injected with 
saline, human AFSC, or conditioned media from human AFSC (AFSC-CM), then reperfused for 
2 hours. Following this protocol, the infarct size was significantly smaller in the AFSC and 
AFSC-CM treated groups compared to the saline control (63). The infarct size was determined 
by treatment of the hearts with 2,3,5-triphenyltetrazolium chloride, which identifies necrotic 
areas (64).  
After 2 hours of reperfusion, AFSC were found in the heart, spleen, and lungs of the rats, 
at increasing concentrations of cells in that order. Surprisingly, no AFSC were found in the liver. 
Furthermore, only 10% of AFSC in the cardiac tissue expressed apoptotic protein caspase-3, 
whereas approximately 32% of AFSC in the heart stained for von Willebrand factor, and 
approximately 82% of cells stained for alpha-smooth muscle α-actin. Rats treated with AFSC or 
AFSC-CM had significantly reduced levels of myocardial apoptosis, as demonstrated by reduced 
TUNEL-positive apoptotic cardiac cells and reduced apoptotic active caspase-3-positive cells. 
AFSC were found to secrete the actin monomer-binding protein thymosin β4, which has been 
shown to be cardioprotective. Given the short time over which AFSC provide a benefit and the 
finding that they secrete thymosin β4, the authors hypothesize that the benefit is provided 
through an in situ paracrine effect (63). 
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Immune response and pathologic differentiation of injected AFSC 
In studies without the use of immunosuppressants, human c-kit sorted AFSC were seen to 
be acutely rejected after injection into the infarct region of rats. An inflammatory response was 
evoked in the cell-injected region in rats with an induced MI or without, regardless of whether 
they were immuno-competent, immuno-suppressed, or immuno-deficient (47). This result was 
disappointing because researchers had hypothesized that AFSC would be immune privileged in 
much the same way as MSC. The researchers speculated that sorting for c-kit may have actually 
made the cells more immunogenic, though it appears the cells that were used lacked c-kit 
expression after passaging and at the time of injection (47). However, as this experiment was 
cross-species, with human AFSC injected into rats, it may still be possible to use AF cells in an 
allogenic fashion, in addition to a potential autologous use for congenital defects.  
A key issue in using AFSC for the therapeutic applications is to ensure that the cells 
differentiate properly based on the needs of the clinical application. Interestingly, chondro-
osteogenic structures were observed in some hearts after injection of AFSC (47, 65). These 
masses were found in the subendocardial zone of infarct hearts, and the chondrogenic and 
osteogenic nature of the masses was confirmed with histology (65). It was originally 
hypothesized that the chondro-osteogenic masses resulted due to AFSC injection (47), but it was 
later found that the masses appeared in approximately 50% of rat hearts with induced MI, 
regardless of AFSC injection, and infarct size was more correlated with formation of chondro-
osteogenic masses than injection of AFSC (65). Injection of AFSC in the absence of MI did not 
lead to the formation of any chondro-osteogenic masses; therefore, it was concluded that 
chondro-osteogenic masses present independent of stem cell injection following MI (65). 
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Heart Valve Tissue Engineering with AFSC 
Disease or degeneration in the heart valves leads to morbidity and mortality (66) in both 
young and adult patients. Heart valve diseases range from congenital malformations to age-
dependent tissue degenerations, constituting a significant clinical challenge. Especially, there is a 
tremendous need to properly repair malfunctioning heart valves in pediatric tissue engineering 
since congenital heart defects usually require surgical procedures to correct the problem (67). 
Therefore, there has been a growing need for living autologous grafts as tissue replacements (67, 
68). Current replacement heart valves include mechanical and bioprosthetic types with certain 
limitations (67, 69). For example, mechanical valves may cause thrombogenesis (67) and are 
susceptible to infections (70). Similarly, bioengineered heart valves may succumb to 
calcification and possess poor durability (71). In addition, the existing strategies utilize 
prostheses without the capacity to grow (67). Fabrication of autologous heart valve replacements 
is preferred particularly for pediatric applications (67, 72, 73) because clinically it is essential for 
an engineered tissue to have the ability to grow and remodel as the patient grows up (67). It is of 
vital importance to correct congenital defects early on to prevent further damage (67). Therefore, 
fabrication of prenatal autologous implants may be useful for hindering secondary damages in 
the newborn (68, 72, 74) 
The ideal tissue engineered heart valves would allow for growth and remodeling, ensure 
complete closure and be nonthrombogenic. Tissue engineered heart valves can be fabricated 
using different approaches, such as seeding cells in decellularized tissues or synthetic scaffolds. 
For instance, autologous engineered heart valve constructs have been generated using the latter 
technique (75). In another attempt to create an autologous heart valve, biodegradable scaffolds 
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were seeded with MSC and implanted in the pulmonary valve position in a juvenile sheep model 
(76). However, major limitations remain in the integrity of the ECM and functionality of the 
final valve construct (69). Calcification, stenosis, fibrosis, and inadequate elastin production in 
the engineered heart valves are additional major challenges. 
Finding an ideal cell source for engineering heart valves can be challenging in pediatric 
tissue engineering (67). To avoid immunorejection problems, the use of autologous cells may be 
important. Although clinically important, a reliable cell source for generation of autologous 
grafts has not been identified yet (67). There are a number of different cell sources to engineer 
heart valves, such as AFSC (68, 72-74), chorionic villi-derived cells (67, 68, 74), umbilical cord 
blood cells (67, 68, 74, 77-81), endothelial progenitor cells (74, 82), bone marrow-derived cells 
(74, 81, 83), adipose-derived cells (74, 84) and pluripotent stem cells (74, 85). Among these, 
adult stem cells have been reported to be promising cell sources to restore and maintain tissue 
function (68). Adult stem cells are usually isolated from blood (68, 86) or bone marrow (68, 86). 
Alternatively, fetal progenitor cells can be used as an autologous cell type for tissue growth and 
remodeling. The progenitor cells demonstrate plastic behavior with potential to differentiate into 
various lineages (73). 
The use of an appropriate cell type is important to generate functional biological 
substitutes to treat congenital tissue malformations. Moreover, the choice of 3D scaffold and 
biological or mechanical stimuli are critical features for engineered implants. Human cells that 
are isolated from fetal sources have been shown to be feasible to generate neo-tissues (68). With 
advanced imaging techniques, it is now possible to detect congenital disorders prior to birth. 
Harvesting cells from AF during pregnancy may create unique opportunities to fabricate 
autologous tissue engineered heart valves, which could be ready by birth (67, 68). Current 
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strategies to repair congenital valvular defects require reoperations as somatic growth progresses. 
For this reason, AFSC that are isolated during pregnancy could be a great alternative to treat 
such congenital disorders. AF has previously been used as a powerful source to isolate 
progenitor cells (68, 72, 73). AFSC are readily accessible (87), easy to harvest, isolate and 
expand (68, 74, 87). The protocol to isolate amniotic fluid is a simple, routine, and relatively 
low-risk procedure to the mother and the child (67, 68, 73) making this cell type more 
advantageous compared to the other available sources. Additionally, AFSC contain multiple 
types of stem cells, which can maintain their proliferation ability while differentiating into 
different lineages and do not lead to the formation of tumors (87).   
Studies have demonstrated that heart valve leaflets can be engineered using AFSC 
(Figure 1) (56). In one report, AFSC were isolated from the AF by CD133-affinity magnetic 
beads (72). Synthetic non-degradable polymers were used as scaffolds and seeded with both 
CD133+ and CD133- AFSC to fabricate tissue engineered valve leaflets. These valves were then 
conditioned in a bioreactor to mature the resulting constructs. It was found that the engineered 
construct was covered with AFSC and remained functional following 28 days of in vitro culture. 
In another study, AFSC were studied for their potential in adult heart valve tissue formation (73). 
Here the authors used cryopreserved AFSC, which were frozen at their seventh passage for four 
months. They demonstrated that both CD133+ and CD133- AFSC preserved their stem cell 
phenotypes after cryopreservation. This in vitro study demonstrated that heart valve leaflets 
could be fabricated by seeding synthetic polymers with cryopreserved AFSC, indicating their 
high potential to be used as a long-term autologous cell source for heart valve tissue engineering. 
In a similar study, AFSC were used to seed synthetic leaflet scaffolds to fabricate in vitro 
engineered heart valves (68). The valve leaflets were then endothelialized by endothelial 
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progenitor cells (EPCs), which were derived from amniotic fluid and conditioned in a bioreactor. 
The resulting constructs were analyzed for their chemical, biological and mechanical properties. 
These neo-tissues were shown to exhibit similar properties with native heart valves with 
functional endothelium demonstrating great potential for tissue engineering.  
Collectively, AFSC have been illustrated to be an effective cell source for fabricating 
engineered heart valves. This could potentially enable the generation of heart valve constructs 
ready by birth to treat congenital heart malformations with important implications for pediatric 
tissue engineering research.  
 
Vascular therapies utilizing AFSC 
Cardiovascular diseases constitute a major focus in therapeutic and engineering 
approaches to treat vascular malfunctions (88, 89). One of the main challenges in cardiovascular 
tissue engineering is to repair the damage in endothelium and further endothelialize artificial 
grafts or constructs for in vivo applications (77). Engineering strategies could be utilized for 
generation of artificial tissue replacements for damaged or diseased vascular tissues by 
controlling cell-material interactions (90, 91).  Endothelial cell lines may be used with 
biomaterials to treat vascular diseases in therapeutic and engineering approaches. 
Endothelialization could be achieved with different types of cells, such as ESC, AFSC, EPC or 
human umbilical vein cord endothelial cells (HUVEC).   
Differentiation of AFSC into an endothelial lineage has been successfully demonstrated 
by Benavides et al. (18) In this example, the AF, originally isolated for therapeutic purposes, was 
enriched by an immunoselection for expression of c-kit. Subsequently, these c-kit+ cells were 
cultured in endothelial growth medium supplemented by different doses of vascular endothelial 
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growth factor (VEGF) (1-100 ng/mL) for 14 days. AFSC-derived endothelial cells were shown 
to express endothelial markers, such as vascular endothelial growth factor receptor-2 (VEGF-
R2), von Willebrand factor (vWF), CD31, endothelial nitric oxide synthase (eNOS), and vascular 
endothelial cadherin (VE-cadherin). These cells also demonstrated endothelial morphology and 
formed interconnected networks on Matrigel coated culture plates. Furthermore, uptake of 
acetylated low-density lipoprotein (ac-LDL), and production of nitric oxide and VEGF were 
assayed to confirm functionality of resulting endothelial cells. Sample images of AFSC-derived 
endothelial cells are shown in Figure 2. This could have important implications in 
vascularization of artificial tissues. 
  There are a number of different factors, such as mechanical forces (92), oxygen tension 
(51), growth factors or cytokines (93) that can be used to promote differentiation of AFSC into 
an endothelial lineage. In one study, AFSC were cultured in endothelial media for three weeks to 
induce endothelial differentiation (51). Expressions of vWF, CD31, and eNOS were used to 
confirm endothelial lineage by (real time) RT-PCR. The function of the resulting endothelial 
cells was demonstrated by the uptake of ac-LDL and formation of vascular networks on a 
Matrigel coating. Endothelial cell markers were shown to be over-expressed when AFSC were 
further exposed to physiological shear stress conditions. Moreover, exposure to hypoxic 
environment induced the expression of angiogenic factors, such as hepatocyte growth factor 
(HGF), placental growth factor (PGF), and VEGF by endothelial cells. This study demonstrates 
that AFSC are a promising cell source, which can be differentiated into endothelial cells for 
potential applications in cardiovascular medicine.  
Another major limitation in cardiovascular tissue engineering is the vascularization of 
injured myocardium (52). Cardiovascular type differentiation can be achieved by the use of 
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isolated stem cells from different sources, such as adipose tissue (94), bone marrow (95), 
embryonic (96), or AF (15, 17, 51, 97-100). AFSC offer several advantages over embryonic or 
adult stem cells. For instance, they proliferate quickly, have the ability to differentiate into cells 
from all three germ layers (15), express pluripotency markers indicative of embryonic and adult 
stem cells (53, 101, 102), and do not form teratomas (103). For these reasons, AFSC are a 
promising cell source to vascularize cardiovascular tissues. This ability is of great importance for 
various applications. For example, it has been reported that the contractile function of the cardiac 
muscle could be restored through proper vascularization (104). In addition, it may be possible to 
prevent deterioration of the muscle tissue by inducing angiogenesis in ischemic cardiac injuries.  
 
Limitations of AFSC 
AFSC have many potential advantages over alternative cell sources for cardiovascular 
tissue engineering including broad multipotency (15), lack of tumor formation (15), and the 
possibility of using autologous cells for congenital heart defects (18). Despite the promise AFSC 
hold, there are still limitations to this cell source. The lack of agreement on isolation and culture 
method, as displayed in Table 1, is one limit on the use of AFSC as the differences in isolation 
and culture method make it uncertain if the same populations of cells are being compared across 
experiments. Another limitation of AFSC for cardiac muscle tissue engineering is that 
functionally mature contracting cardiomyocytes have not yet been obtained (48, 50).  
 
Conclusion 
AFSC are a promising cell source for cardiovascular therapies, regenerative medicine and 
vascular tissue engineering. AFSC hold specific utility in the repair of congenital defects in a 
 Page 23 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
24 
 24 
newborn infant or late-term fetus, because the fluid can be collected with relatively minimal risk, 
isolated stem cells have a greater differentiation potential than other adult stem cell sources, and 
generated cell-containing constructs are genetically matched to the fetus or newborn infant and 
can be used for repair without risk of immunorejection. Research studies have demonstrated that 
AFSC could induce or enhance the enothelialization and vascularization processes in engineered 
constructs, and can be used in cardiac muscle tissue, cardiac valve and vessel tissue engineering 
applications. However, research into the characterization, processing and use of these cells is 
limited, especially compared to other adult MSC and ESC sources. Further basic research in this 
area is necessary to lead us to these goals. 
 
Acknowledgments 
JJP was funded by the NSF GRFP (0940902). JGJ was funded by the NSF CAREER and AHA 
BGIA. AK was funded by the NIH (EB012597, HL099073, DE019024) and the NSF CAREER 
award.
 Page 24 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
25 
 25 
References 
1. Kochanek KD, Kirmeyer SE, Martin JA, Strobino DM, Guyer B. Annual summary of 
vital statistics: 2009. Pediatrics 129, 338, 2012. 
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart 
disease and stroke statistics--2010 update: A report from the american heart association. 
Circulation 121, e46, 2010. 
3. Jonas R. Comprehensive surgical management of congenital heart disease. London: 
Hodder Arnold, 2004. 
4. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective 
evaluation of risk of sudden cardiac death after operation for common congenital heart 
defects. J Am Coll Cardiol 32, 245, 1998. 
5. Brown JW, Rodefeld MD, Ruzmetov M, Eltayeb O, Yurdakok O, Turrentine MW. 
Surgical valvuloplasty versus balloon aortic dilation for congenital aortic stenosis: Are 
evidence-based outcomes relevant? Ann Thorac Surg 94, 146, 2012. 
6. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and 
thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of 
thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice 
guidelines. Chest 141, e576S, 2012. 
7. Pok S, Jacot JG. Biomaterials advances in patches for congenital heart defect repair. J 
Cardiovasc Transl Res 4, 646, 2011. 
8. Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of 
regenerative cardiovascular medicine. Science 322, 1494, 2008. 
 Page 25 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
26 
 26 
9. Vunjak-Novakovic G, Lui KO, Tandon N, Chien KR. Bioengineering heart muscle: A 
paradigm for regenerative medicine. Annu Rev Biomed Eng 13, 245, 2011. 
10. Hibino N, McGillicuddy E, Matsumura G, Ichihara Y, Naito Y, Breuer C, et al. Late-
term results of tissue-engineered vascular grafts in humans. J Thorac Cardiovasc Surg 139, 
431, 2010. 
11. Hogler W, Baumann U, Kelly D. Endocrine and bone metabolic complications in 
chronic liver disease and after liver transplantation in children. J Pediatr Gastroenterol 
Nutr 54, 313, 2012. 
12. Sadler TW. Langman's medical embryology. 10th ed. Philadelphia: Lippincott 
Williams & Wilkins, 2006. 
13. Antonucci I, Pantalone A, De Amicis D, D'Onofrio S, Stuppia L, Palka G, et al. Human 
amniotic fluid stem cells culture onto titanium screws: A new perspective for bone 
engineering. J Biol Regul Homeost Agents 23, 277, 2009. 
14. Arnhold S, Gluer S, Hartmann K, Raabe O, Addicks K, Wenisch S, et al. Amniotic-fluid 
stem cells: Growth dynamics and differentiation potential after a cd-117-based selection 
procedure. Stem Cells Int 2011, 715341, 2011. 
15. De Coppi P, Bartsch G, Jr., Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of 
amniotic stem cell lines with potential for therapy. Nat Biotechnol 25, 100, 2007. 
16. Prusa AR, Marton E, Rosner M, Bernaschek G, Hengstschlager M. Oct-4-expressing 
cells in human amniotic fluid: A new source for stem cell research? Hum Reprod 18, 1489, 
2003. 
 Page 26 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
27 
 27 
17. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal 
stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. 
Hum Reprod 19, 1450, 2004. 
18. Benavides OM, Petsche JJ, Moise KJ, Johnson A, Jacot J. Evaluation of endothelial cells 
differentiated from amniotic fluid-derived stem cells. Tissue Eng Part A 18, 1123, 2012. 
19. You Q, Tong X, Guan Y, Zhang D, Huang M, Zhang Y, et al. The biological 
characteristics of human third trimester amniotic fluid stem cells. J Int Med Res 37, 105, 
2009. 
20. Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Buiatiotis S, et al. 
Molecular and phenotypic characterization of human amniotic fluid cells and their 
differentiation potential. Cell Res 16, 329, 2006. 
21. Niwa H, Miyazaki J, Smith AG. Quantitative expression of oct-3/4 defines 
differentiation, dedifferentiation or self-renewal of es cells. Nat Genet 24, 372, 2000. 
22. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, et al. Primary structure 
and functional expression of rat and human stem cell factor dnas. Cell 63, 203, 1990. 
23. Seo JM, Sohn MY, Suh JS, Atala A, Yoo JJ, Shon YH. Cryopreservation of amniotic fluid-
derived stem cells using natural cryoprotectants and low concentrations of 
dimethylsulfoxide. Cryobiology 62, 167, 2011. 
24. You Q, Cai L, Zheng J, Tong X, Zhang D, Zhang Y. Isolation of human mesenchymal 
stem cells from third-trimester amniotic fluid. Int J Gynaecol Obstet 103, 149, 2008. 
25. Sessarego N, Parodi A, Podesta M, Benvenuto F, Mogni M, Raviolo V, et al. 
Multipotent mesenchymal stromal cells from amniotic fluid: Solid perspectives for clinical 
application. Haematologica 93, 339, 2008. 
 Page 27 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
28 
 28 
26. Kaviani A, Guleserian K, Perry TE, Jennings RW, Ziegler MM, Fauza DO. Fetal tissue 
engineering from amniotic fluid. J Am Coll Surg 196, 592, 2003. 
27. Steigman SA, Fauza DO. Isolation of mesenchymal stem cells from amniotic fluid and 
placenta.  Curr protoc stem cell biol 2007. 
28. Steigman SA, Armant M, Bayer-Zwirello L, Kao GS, Silberstein L, Ritz J, et al. 
Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell 
manufacturing protocol. J Pediatr Surg 43, 1164, 2008. 
29. Filioli Uranio M, Valentini L, Lange-Consiglio A, Caira M, Guaricci AC, L'Abbate A, et 
al. Isolation, proliferation, cytogenetic, and molecular characterization and in vitro 
differentiation potency of canine stem cells from foetal adnexa: A comparative study of 
amniotic fluid, amnion, and umbilical cord matrix. Mol Reprod Dev 78, 361, 2011. 
30. Lovati AB, Corradetti B, Lange Consiglio A, Recordati C, Bonacina E, Bizzaro D, et al. 
Comparison of equine bone marrow-, umbilical cord matrix and amniotic fluid-derived 
progenitor cells. Vet Res Commun 35, 103, 2011. 
31. Mauro A, Turriani M, Ioannoni A, Russo V, Martelli A, Di Giacinto O, et al. Isolation, 
characterization, and in vitro differentiation of ovine amniotic stem cells. Vet Res Commun 
34 S25, 2010. 
32. Peister A, Deutsch ER, Kolambkar Y, Hutmacher DW, Guldberg RE. Amniotic fluid 
stem cells produce robust mineral deposits on biodegradable scaffolds. Tissue Eng Part A 
15, 3129, 2009. 
33. Perin L, Giuliani S, Jin D, Sedrakyan S, Carraro G, Habibian R, et al. Renal 
differentiation of amniotic fluid stem cells. Cell Prolif 40, 936, 2007. 
 Page 28 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
29 
 29 
34. Siegel N, Rosner M, Unbekandt M, Fuchs C, Slabina N, Dolznig H, et al. Contribution 
of human amniotic fluid stem cells to renal tissue formation depends on mtor. Hum Mol 
Genet 19, 3320, 2010. 
35. Gekas J, Walther G, Skuk D, Bujold E, Harvey I, Bertrand OF. In vitro and in vivo 
study of human amniotic fluid-derived stem cell differentiation into myogenic lineage. Clin 
Exp Med 10, 1, 2010. 
36. Carraro G, Perin L, Sedrakyan S, Giuliani S, Tiozzo C, Lee J, et al. Human amniotic 
fluid stem cells can integrate and differentiate into epithelial lung lineages. Stem Cells 26, 
2902, 2008. 
37. Siegel N, Valli A, Fuchs C, Rosner M, Hengstschlager M. Induction of 
mesenchymal/epithelial marker expression in human amniotic fluid stem cells. Reprod 
Biomed Online 19, 838, 2009. 
38. Arnhold S, Post C, Gluer S, Hoopmann M, Wenisch S, Volpers C, et al. Neuronal 
characteristics of amniotic fluid derived cells after adenoviral transformation. Cell Biol Int 
32, 1559, 2008. 
39. Jezierski A, Gruslin A, Tremblay R, Ly D, Smith C, Turksen K, et al. Probing stemness 
and neural commitment in human amniotic fluid cells. Stem Cell Rev 6, 199, 2010. 
40. Mareschi K, Rustichelli D, Comunanza V, De Fazio R, Cravero C, Morterra G, et al. 
Multipotent mesenchymal stem cells from amniotic fluid originate neural precursors with 
functional voltage-gated sodium channels. Cytotherapy 11, 534, 2009. 
41. McLaughlin D, Tsirimonaki E, Vallianatos G, Sakellaridis N, Chatzistamatiou T, 
Stavropoulos-Gioka C, et al. Stable expression of a neuronal dopaminergic progenitor 
 Page 29 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
30 
 30 
phenotype in cell lines derived from human amniotic fluid cells. J Neurosci Res 83, 1190, 
2006. 
42. Orciani M, Emanuelli M, Martino C, Pugnaloni A, Tranquilli AL, Di Primio R. Potential 
role of culture mediums for successful isolation and neuronal differentiation of amniotic 
fluid stem cells. Int J Immunopathol Pharmacol 21, 595, 2008. 
43. Pfeiffer S, Boyle J, Daly S, Dowd E, Haase J, McLaughlin D. Human amniocytes 
regulate serotonin levels by active uptake and express genes suggestive of a wider role in 
facilitating neurotransmitter regulation in the fetal environment. Stem Cells Dev 20, 341, 
2011. 
44. Pfeiffer S, McLaughlin D. In vitro differentiation of human amniotic fluid-derived 
cells: Augmentation towards a neuronal dopaminergic phenotype. Cell Biol Int 34, 959, 
2010. 
45. Donaldson AE, Cai J, Yang M, Iacovitti L. Human amniotic fluid stem cells do not 
differentiate into dopamine neurons in vitro or after transplantation in vivo. Stem Cells Dev 
18, 1003, 2009. 
46. Bollini S, Pozzobon M, Nobles M, Riegler J, Dong X, Piccoli M, et al. In vitro and in 
vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev 7, 364, 2011. 
47. Chiavegato A, Bollini S, Pozzobon M, Callegari A, Gasparotto L, Taiani J, et al. Human 
amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of 
normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol 42, 746, 
2007. 
48. Guan X, Delo DM, Atala A, Soker S. In vitro cardiomyogenic potential of human 
amniotic fluid stem cells. J Tissue Eng Regen Med 5, 220, 2011. 
 Page 30 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
31 
 31 
49. Lee WY, Wei HJ, Lin WW, Yeh YC, Hwang SM, Wang JJ, et al. Enhancement of cell 
retention and functional benefits in myocardial infarction using human amniotic-fluid 
stem-cell bodies enriched with endogenous ecm. Biomaterials 32, 5558, 2011. 
50. Yeh YC, Wei HJ, Lee WY, Yu CL, Chang Y, Hsu LW, et al. Cellular cardiomyoplasty with 
human amniotic fluid stem cells: In vitro and in vivo studies. Tissue Eng Part A 16, 1925, 
2010. 
51. Zhang P, Baxter J, Vinod K, Tulenko TN, Di Muzio PJ. Endothelial differentiation of 
amniotic fluid-derived stem cells: Synergism of biochemical and shear force stimuli. Stem 
Cells Dev 18, 1299, 2009. 
52. Iop L, Chiavegato A, Callegari A, Bollini S, Piccoli M, Pozzobon M, et al. Different 
cardiovascular potential of adult- and fetal-type mesenchymal stem cells in a rat model of 
heart cryoinjury. Cell Transplant 17, 679, 2008. 
53. Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO. The amniotic 
fluid as a source of cells for fetal tissue engineering. J Pediatr Surg 36, 1662, 2001. 
54. Yeh YC, Lee WY, Yu CL, Hwang SM, Chung MF, Hsu LW, et al. Cardiac repair with 
injectable cell sheet fragments of human amniotic fluid stem cells in an immune-
suppressed rat model. Biomaterials 31, 6444, 2010. 
55. Weber B, Emmert MY, Hoerstrup SP. Stem cells for heart valve regeneration. Swiss 
Med Wkly 142, w13622, 2012. 
56. Weber B, Emmert MY, Behr L, Schoenauer R, Brokopp C, Drogemuller C, et al. 
Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal 
circulation. Biomaterials 33, 4031, 2012. 
 Page 31 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
32 
 32 
57. Shim WS, Jiang S, Wong P, Tan J, Chua YL, Tan YS, et al. Ex vivo differentiation of 
human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem Biophys Res 
Commun 324, 481, 2004. 
58. Chen WQ, Siegel N, Li L, Pollak A, Hengstschlager M, Lubec G. Variations of protein 
levels in human amniotic fluid stem cells cd117/2 over passages 5-25. J Proteome Res 8, 
5285, 2009. 
59. Noort WA, Oerlemans MI, Rozemuller H, Feyen D, Jaksani S, Stecher D, et al. Human 
versus porcine mesenchymal stromal cells: Phenotype, differentiation potential, 
immunomodulation and cardiac improvement after transplantation. J Cell Mol Med 16, 
1827, 2012. 
60. Numasawa Y, Kimura T, Miyoshi S, Nishiyama N, Hida N, Tsuji H, et al. Treatment of 
human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of 
cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. Stem 
Cells 29, 1405, 2011. 
61. Peng C, Yang K, Xiang P, Zhang C, Zou L, Wu X, et al. Effect of transplantation with 
autologous bone marrow stem cells on acute myocardial infarction. Int J Cardiol 2011. 
62. Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, et al. 
Rationale and design of the transendocardial injection of autologous human cells (bone 
marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure 
secondary to myocardial infarction (tac-hft) trial: A randomized, double-blind, placebo-
controlled study of safety and efficacy. Am Heart J 161, 487, 2011. 
 Page 32 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
33 
 33 
63. Bollini S, Cheung KK, Riegler J, Dong X, Smart N, Ghionzoli M, et al. Amniotic fluid 
stem cells are cardioprotective following acute myocardial infarction. Stem Cells Dev 20, 
1985, 2011. 
64. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, et al. Early 
phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium 
chloride tissue enzyme staining technique. Am Heart J 101, 593, 1981. 
65. Delo DM, Guan X, Wang Z, Groban L, Callahan M, Smith T, et al. Calcification after 
myocardial infarction is independent of amniotic fluid stem cell injection. Cardiovasc 
Pathol 20, e69, 2011. 
66. Filova E, Straka F, Mirejovsky T, Masin J, Bacakova L. Tissue-engineered heart 
valves. Physiological Research 58, s141, 2009. 
67. Schmidt D, Mol A, Breymann C, Achermann J, Odermatt B, Gossi M, et al. Living 
autologous heart valves engineered from human prenatally harvested progenitors. 
Circulation 114, I125, 2006. 
68. Weber B, Zeisberger SM, Hoerstrup SP. Prenatally harvested cells for cardiovascular 
tissue engineering: Fabrication of autologous implants prior to birth. Placenta 32, S316, 
2011. 
69. Sacks MS, Schoen FJ, Mayer JE. Bioengineering challenges for heart valve tissue 
engineering. Annual Review of Biomedical Engineering 11, 289, 2009. 
70. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications 
in patients with mechanical heart-valve prostheses. Circulation 89, 635, 1994. 
71. Schoen FJ, Levy RJ. Pathology of substitute heart-valves-new concepts and 
developments. J Card Surg 9, 222, 1994. 
 Page 33 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
34 
 34 
72. Schmidt D, Achermann J, Odermatt B, Breymann C, Mol A, Genoni M, et al. Prenatally 
fabricated autologous human living heart valves based on amniotic fluid-derived 
progenitor cells as single cell source. Circulation 116, i64, 2007. 
73. Schmidt D, Achermann J, Odermatt B, Genoni M, Zund G, Hoerstrup SP. 
Cryopreserved amniotic fluid-derived cells: A life-long autologous fetal stem cell source for 
heart valve tissue engineering. J Heart Valve Dis 17, 446, 2008. 
74. Weber B, Hoerstrup SP. Regenerating heart valves. In: Cohen IS, Gaudette GR, eds. 
Regenerating the heart: Stem cells and the cardiovascular system 2011. pp. 403-442. 
75. Ye Q, Zund G, Jockenhoevel S, Hoerstrup SP, Schoeberlein A, Grunenfelder J, et al. 
Tissue engineering in cardiovascular surgery: New approach to develop completely human 
autologous tissue. European Journal of Cardio-Thoracic Surgery 17, 449, 2000. 
76. Sutherland FWH, Perry TE, Yu Y, Sherwood MC, Rabkin E, Masuda Y, et al. From 
stem cells to viable autologous semilunar heart valve. Circulation 111, 2783, 2005. 
77. Schmidt D, Breymann C, Weber A, Guenter CI, Neuenschwander S, Zund G, et al. 
Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular 
grafts. Annals of Thoracic Surgery 78, 2094, 2004. 
78. Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical 
cord blood. British Journal of Haematology 109, 235, 2000. 
79. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, et al. 
Engineering robust and functional vascular networks in vivo with human adult and cord 
blood-derived progenitor cells. Circulation Research 103, 194, 2008. 
80. Bieback K, Kern S, Kluter H, Eichler H. Critical parameters for the isolation of 
mesenchymal stem cells from umbilical cord blood. Stem Cells 22, 625, 2004. 
 Page 34 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
35 
 35 
81. Schmidt D, Stock UA, Hoerstrup SP. Tissue engineering of heart valves using 
decellularized xenogeneic or polymeric starter matrices. Philos Trans R Soc Lond B Biol Sci 
362, 1505, 2007. 
82. Kim S, Von Recum H. Endothelial stem cells and precursors for tissue engineering: 
Cell source, differentiation, selection, and application. Tissue Engineering Part B-Reviews 
14, 133, 2008. 
83. Perry TE, Kaushal S, Sutherland FWH, Guleserian KJ, Bischoff J, Sacks M, et al. Bone 
marrow as a cell source for tissue engineering heart valves. Annals of Thoracic Surgery 75, 
761, 2003. 
84. Colazzo F, Sarathchandra P, Smolenski RT, Chester AH, Tseng YT, Czernuszka JT, et 
al. Extracellular matrix production by adipose-derived stem cells: Implications for heart 
valve tissue engineering. Biomaterials 32, 119, 2011. 
85. Zhang JH, Wilson GF, Soerens AG, Koonce CH, Yu JY, Palecek SP, et al. Functional 
cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research 
104, E30, 2009. 
86. Schmidt D, Dijkman PE, Driessen-Mol A, Stenger R, Mariani C, Puolakka A, et al. 
Minimally-invasive implantation of living tissue engineered heart valves: A comprehensive 
approach from autologous vascular cells to stem cells. J Am Coll Cardiol 56, 510, 2010. 
87. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: Decellularization 
and recellularization of three-dimensional matrix scaffolds. In: Yarmush ML, Duncan JS, 
Gray ML, eds. Annual review of biomedical engineering 2011. pp. 27-53. 
 Page 35 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
36 
 36 
88. Camci-Unal G, Nichol JW, Bae H, Tekin H, Bischoff J, Khademhosseini A. Hydrogel 
surfaces to promote attachment and spreading of endothelial progenitor cells. J Tissue Eng 
Regen Med 2012. 
89. de Mel A, Jell G, Stevens MM, Seifalian AM. Biofunctionalization of biomaterials for 
accelerated in situ endothelialization: A review. Biomacromolecules 9, 2969, 2008. 
90. Camci-Unal G, Aubin H, Ahari AF, Bae H, Nichol JW, Khademhosseini A. Surface-
modified hyaluronic acid hydrogels to capture endothelial progenitor cells. Soft Matter 6, 
5120, 2010. 
91. Avci-Adali M, Paul A, Ziemer G, Wendel HP. New strategies for in vivo tissue 
engineering by mimicry of homing factors for self-endothelialisation of blood contacting 
materials. Biomaterials 29, 3936, 2008. 
92. Wang H, Riha GM, Yan S, Li M, Chai H, Yang H, et al. Shear stress induces endothelial 
differentiation from a murine embryonic mesenchymal progenitor cell line. Arterioscler 
Thromb Vasc Biol 25, 1817, 2005. 
93. Liu JW, Dunoyer-Geindre S, Serre-Beinier V, Mai G, Lambert JF, Fish RJ, et al. 
Characterization of endothelial-like cells derived from human mesenchymal stem cells. 
Journal of Thrombosis and Haemostasis 5, 826, 2007. 
94. Cao Y, Sun Z, Liao LM, Meng Y, Han Q, Zhao RCH. Human adipose tissue-derived stem 
cells differentiate into endothelial cells in vitro and improve postnatal neovascularization 
in vivo. Biochemical and Biophysical Research Communications 332, 370, 2005. 
95. Oswald J, Boxberger S, Jorgensen B, Feldmann S, Ehninger G, Bornhauser M, et al. 
Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22, 
377, 2004. 
 Page 36 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
37 
 37 
96. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie XY, et al. Differentiation, survival, and 
function of embryonic stem cell-derived endothelial cells for ischemic heart disease. 
Circulation 116, I46, 2007. 
97. Kunisaki SM, Armant M, Kao GS, Stevenson K, Kim H, Fauza DO. Tissue engineering 
from human mesenchymal amniocytes: A prelude to clinical trials. J Pediatr Surg 42, 974, 
2007. 
98. Moorefield EC, Delo DM, De Coppi P, Atala A. Amniotic fluid and placental stem cells.  
Pluripotent stem cells 2010. pp. 113-135. 
99. Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, et al. Human amniotic fluid-
derived stem cells have characteristics of multipotent stem cells. Cell Prolif 40, 75, 2007. 
100. Siegel N, Rosner M, Hanneder M, Freilinger A, Hengstschlager M. Human amniotic 
fluid stem cells: A new perspective. Amino Acids 35, 291, 2008. 
101. Prusa AR, Marton E, Rosner M, Bettelheim D, Lubec G, Pollack A, et al. Neurogenic 
cells in human amniotic fluid. Am J Obstet Gynecol 191, 309, 2004. 
102. Cipriani S, Bonini D, Marchina E, Balgkouranidou I, Caimi L, Zucconi GG, et al. 
Mesenchymal cells from human amniotic fluid survive and migrate after transplantation 
into adult rat brain. Cell Biology International 31, 845, 2007. 
103. Hilfiker A, Kasper C, Hass R, Haverich A. Mesenchymal stem cells and progenitor 
cells in connective tissue engineering and regenerative medicine: Is there a future for 
transplantation? Langenbecks Archives of Surgery 396, 489, 2011. 
104. Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial 
regeneration. Physiological Reviews 85, 1373, 2005. 
 
 Page 37 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
38 
 38 
  
 Page 38 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
39 
 39 
 Sorting Medium References 
 - αMEM, 10% FBS 14, 38, 40 
 c-kit αMEM, 10% FBS 14 
* - αMEM, 15% FBS, 20% Chang (Irvine Scientific) 23, 52 
* c-kit αMEM, 15% FBS, 20% Chang (Irvine Scientific) 15, 18, 32-34, 36, 37, 45-48, 58, 65 
* - αMEM, 20% FBS, 4 ng/ml bFGF 17, 49, 50, 54 
 - M199 medium, 10% FBS 20, 51 
 - F-10 nutrient medium, 10% FBS 16, 41, 43 
 - F-10 nutrient medium, 20% FBS 44 
 - DMEM, 20% FBS 20, 39 
 - DMEM, 10% FBS, 10 ng/ml EGF 29, 99 
 - DMEM, 10% FBS, 10 ng/ml bFGF 30 
 - DMEM, 20% FBS, 5-10 ng/ml bFGF 26-28, 31, 97 
 - DMEM, 20% FBS, 10 ng/ml bFGF, 10 ng/ml EGF 19, 24 
* c-kit AmnioMax Medium (Invitrogen), 10% FBS 35, 51 
 - Mesencult medium (Stem Cell Technologies, Inc.) 25 
 - Amniomed (Euroclone) 20 
 
 
 
 
Table 1.  Isolation methods and culture medium for undifferentiated AFSC 
 
Definitions: AFSC – amniotic fluid-derived stem cells; αMEM – alpha modified eagle medium; 
FBS – fetal bovine serum; DMEM – Dulbecco’s modified eagle medium; EGF – epidermal 
growth factor; bFGF – basic fibroblast growth factor 
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Marker Description Results References 
Oct-4 
Transcription factor necessary for 
maintaining pluripotency of ESC 
Positive expression, generally at low levels, by PCR, FC, 
and immunostaining. Found by some to be only expressed 
in some fluid samples.  
16, 17, 20, 23, 24, 
29-31, 35,37, 39-41, 
46, 49-52, 54 
Sox2 
Transcription factor necessary for 
maintaining pluripotency of ESC 
Mixed results: both positive and negative expression by 
PCR reported, as well as positive immunostaining 
20, 39, 48 
Nanog 
Transcription factor necessary for 
maintaining pluripotency of ESC 
Positive expression at low levels by PCR, FC, and 
immunostaining 
39, 40, 49, 50, 54 
SSEA-4 
Stage specific embryonic antigen 4; 
surface antigen found on ESC 
Positive expression by FC and immunostaining 
18, 23, 30, 35, 46, 
49-52, 54 
MHC I Found on every nucleated cell in the body Positive expression by PCR and FC 
17, 18, 23, 25, 28, 
30, 41, 47, 50 
MHC II Found only on antigen presenting cells Negative by PCR and FC 
17, 18, 23, 30, 41, 
47, 50, 52 
CD29, CD44, 
CD73, CD90, 
CD105, CD146 
Markers common on MSC Positive expression by PCR, FC, and immunostaining 
17-20, 23-25, 28-30, 
40, 41, 46-52 
vimentin 
Intermediate filament expressed in 
mesenchymal cells 
Positive expression by PCR and immunostaining 
23, 26, 35, 40, 46, 
47, 52-54 
CD11b, CD14, 
CD34, CD45 
Hematopoietic cell markers Negative by PCR, FC, and/or immunostaining 
17-19, 23-25, 28, 30, 
40, 41, 46-52 
CD117/c-kit 
Stem cell growth factor receptor; expressed 
by hematopoietic stem cells as well as 
variety of other cell types 
Mixed results: positive expression by PCR, but negative to 
only slight (~25%) positive expression by FC 
17, 18, 37, 29, 50 
CD31, CD144, 
CD309 
Endothelial cell markers Negative by FC and immunostaining 
18, 19, 24-26, 47, 
49, 50, 53 
vWF 
von Willebrand Factor; marker of 
endothelial cells 
Mixed results: negative by FC but both positive and 
negative
 
expression by immunostaining reported 
25, 26, 47, 52 
desmin 
Intermediate filament found in the Z-line 
of sarcomeres in muscle 
Negative by immunostaining
 
26, 53 
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Table 2. Characterization of undifferentiated AFSC 
 
Definitions: AFSC – amniotic fluid-derived stem cells; ESC – embryonic stem cells; MSC – mesenchymal stem cells; CD – cluster of 
differentiation; vWF – von Willebrand factor; MHC – major histocompatability complex; SSEA – stage specific embryonic antigen; 
PCR – polymerase chain reaction; FC – flow cytometry 
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Method 
Length of 
culture 
Result References 
Human AFSC and NRVM 
co-culture, 1:4 ratio 
10 days 
5% of AFSC displayed cTnI protein 
expression and sarcomere banding; bi-
nucleated cells observed 
47 
Human AFSC and NRVM 
co-culture, 1:10 ratio 
7 days or 
10 days 
Functional gap junctions observed; Some cells 
observed to express human mitochondria as 
well as cTnT or α-actinin 
48, 50 
Rat AFSC and NRVM co-
culture, 1:4 ratio 
9 days 
Cardiac differentiation observed in 3.5% to 
16% of AFSC, determined by sarcomeric α-
actinin, myosin heavy chain, cTnT, or cTnI 
protein expression; bi-nucleated cells observed 
46, 52 
Cardiomyogenic 
differentiation medium  
15 days No differentiation observed 47, 52 
NRVM-conditioned 
medium 
10 days No differentiation observed 46, 47, 52 
10 μM 5-aza-
2’deoxycytidine for 24 
hours 
10 days 
Increased cTnI and cTnT gene expression; 
decreased Sox2 gene expression; no mature 
sarcomeres or beating cells 
48 
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Table 3. In vitro cardiac differentiation of AFSC 
 
Definitions: AFSC – amniotic fluid-derived stem cells; NRVM  - neonatal rat ventricular myocytes; cTnI – cardiac troponin I; cTnT – 
cardiac troponin T 
  
 Page 44 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
45 
 45 
Treatment Observed results References 
Dissociated AFSC Reduce fibrosis and enlargement of left 
ventricle compared to saline 
control but not as effective as 
aggregated AFSC structures  
Proliferation of AFSC observed  
AFSC found expressing Nkx2.5, cTnT, 
α-actinin, smooth muscle α-actin, 
or von Willebrand Factor  
Majority of cells are quickly lost after 
injection  
49,50,54 
 
 
 
46, 52 
46, 52 
 
 
46, 49, 52, 54 
Aggregated AFSC-ECM structures 
 Cell sheet fragments - AFSC 
plated on thermo-responsive 
hydrogels to form confluent cells 
sheets, then separated into 
fragments 
 Cell bodies - AFSC plated in 
coated wells such that the cells 
were unable to attach and instead 
formed spherical cell bodies 
Undifferentiated state of AFSC 
maintained prior to implantation  
AFSC retained for 4 weeks in rats 
injected with aggregated 
structures  
Significant contractile function 
improvement over both saline 
controls and dissociated AFSC 
injections  
Increased density of vasculature  
49, 54 
 
49, 54 
 
 
49, 54 
 
 
 
54 
Short term effects of dissociated AFSC or 
AFSC-CM (2 hours post-MI) 
Reduced infarct size compared to 
saline treated control  
63 
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Table 4. AFSC implantation in myocardium 
 
Definitions: AFSC – amniotic fluid-derived stem cells; ECM – extracellular matrix; CM – conditioned medium; cTnT – cardiac 
troponin T 
  
 Page 46 of 51
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
47 
 47 
 
 
 Page 47 of 51 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
B:
 R
ev
ie
w
s
A
m
ni
ot
ic
 fl
ui
d-
de
riv
ed
 st
em
 c
el
ls 
fo
r c
ar
di
ov
as
cu
la
r t
iss
ue
 e
ng
in
ee
rin
g 
ap
pl
ic
at
io
ns
 (d
oi:
 10
.10
89
/te
n.T
EB
.20
12
.05
61
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
48 
 48 
Figure 1. AFSC-seeded heart valve leaflets.  
Nonwoven polyglycolic-acid (PGA) scaffolds were dip-coated using Poly-4-Hydroxybutyric acid (P4HB) and seeded with AFSC. 
Reprinted from Weber B., et al. Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. 
Biomaterials 33, 4031, 2012, with permission from Elsevier. 
 
Definitions: AFSC  - amniotic fluid-derived stem cells; PGA – polylycolic-acid; P4HB – poly040hydroxybutyric acid 
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Figure 2. Morphology of AFSC-derived endothelial cells 
Formation of network by AFSC-derived endothelial cells on Matrigel coating (A). Cobblestone-like morphology of confluent AFSC-
derived endothelial cells (B).  
 
Definitions: AFSC – amniotic fluid-derived stem cells 
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